The Human Smoothened Inhibitor PF-04449913 Induced Exit from Quiescence and Loss of Multipotent Drosphila Hematopoietic Progenitor Cells

Giorgia Giordani, Marilena Barraco, Angela Giangrande, Giovanni Martinelli, Viviana Guadagnuolo, Giorgia Simonetti, Giovanni Perini, Roberto Bernardoni

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The efficient treatment of hematological malignancies as Acute Myeloid Leukemia, myelofibrosis and Chronic Myeloid Leukemia, requires the elimination of cancerinitiating cells and the prevention of disease relapse through targeting pathways that stimulate generation and maintenance of these cells. In mammals, inhibition of Smoothened, the key mediator of the Hedgehog signaling pathway, reduces Chronic Myeloid Leukemia progression and propagation. These findings make Smo a candidate target to inhibit maintenance of leukemia-initiating cells. In Drosophila melanogaster the same pathway maintains the hematopoietic precursor cells of the lymph gland, the hematopoietic organ that develops in the larva. Using Drosophila as an in vivo model, we investigated the mode of action of PF-04449913, a smallmolecule inhibitor of the human Smo protein. Drosophila larvae fed with PF-04449913 showed traits of altered hematopoietic homeostasis. These include the development of melanotic nodules, increase of circulating hemocytes, the size increase of the lymph gland and accelerated differentiation of blood cells likely due to the exit of multi-potent precursors from quiescence. Importantly, the Smo inhibition can lead to the complete loss of hematopoietic precursors. We conclude that PF-04449913 inhibits Drosophila Smo blocking the Hh signaling pathway and causing the loss of hematopoietic precursor cells. Interestingly, this is the effect expected in patients treated with PF-04449913: Number decrease of cancer initiating cells in the bone marrow to reduce the risk of leukemia relapse. Altogether our results indicate that Drosophila comprises a model system for the in vivo study of molecules that target evolutionary conserved pathways implicated in human hematological malignancies.

Original languageEnglish
Pages (from-to)55313-55327
Number of pages15
JournalOncotarget
Volume7
Issue number34
DOIs
Publication statusPublished - 28 Jul 2016

Fingerprint

Hematopoietic Stem Cells
Drosophila
Lymph
Hematologic Neoplasms
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Larva
Leukemia
Maintenance
Hemocytes
Primary Myelofibrosis
Hedgehogs
Secondary Prevention
Drosophila melanogaster
Acute Myeloid Leukemia
Bone Marrow Cells
Mammals
Blood Cells
Homeostasis
1-(2-(1H-benzo(d)imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
Recurrence

Cite this

Giordani, G., Barraco, M., Giangrande, A., Martinelli, G., Guadagnuolo, V., Simonetti, G., ... Bernardoni, R. (2016). The Human Smoothened Inhibitor PF-04449913 Induced Exit from Quiescence and Loss of Multipotent Drosphila Hematopoietic Progenitor Cells. Oncotarget, 7(34), 55313-55327. https://doi.org/10.18632/oncotarget.10879
Giordani, Giorgia ; Barraco, Marilena ; Giangrande, Angela ; Martinelli, Giovanni ; Guadagnuolo, Viviana ; Simonetti, Giorgia ; Perini, Giovanni ; Bernardoni, Roberto. / The Human Smoothened Inhibitor PF-04449913 Induced Exit from Quiescence and Loss of Multipotent Drosphila Hematopoietic Progenitor Cells. In: Oncotarget. 2016 ; Vol. 7, No. 34. pp. 55313-55327.
@article{25e28e8354e84e4cb3529c95a167053b,
title = "The Human Smoothened Inhibitor PF-04449913 Induced Exit from Quiescence and Loss of Multipotent Drosphila Hematopoietic Progenitor Cells",
abstract = "The efficient treatment of hematological malignancies as Acute Myeloid Leukemia, myelofibrosis and Chronic Myeloid Leukemia, requires the elimination of cancerinitiating cells and the prevention of disease relapse through targeting pathways that stimulate generation and maintenance of these cells. In mammals, inhibition of Smoothened, the key mediator of the Hedgehog signaling pathway, reduces Chronic Myeloid Leukemia progression and propagation. These findings make Smo a candidate target to inhibit maintenance of leukemia-initiating cells. In Drosophila melanogaster the same pathway maintains the hematopoietic precursor cells of the lymph gland, the hematopoietic organ that develops in the larva. Using Drosophila as an in vivo model, we investigated the mode of action of PF-04449913, a smallmolecule inhibitor of the human Smo protein. Drosophila larvae fed with PF-04449913 showed traits of altered hematopoietic homeostasis. These include the development of melanotic nodules, increase of circulating hemocytes, the size increase of the lymph gland and accelerated differentiation of blood cells likely due to the exit of multi-potent precursors from quiescence. Importantly, the Smo inhibition can lead to the complete loss of hematopoietic precursors. We conclude that PF-04449913 inhibits Drosophila Smo blocking the Hh signaling pathway and causing the loss of hematopoietic precursor cells. Interestingly, this is the effect expected in patients treated with PF-04449913: Number decrease of cancer initiating cells in the bone marrow to reduce the risk of leukemia relapse. Altogether our results indicate that Drosophila comprises a model system for the in vivo study of molecules that target evolutionary conserved pathways implicated in human hematological malignancies.",
keywords = "Drosophila, Leukemia, PF-04449913, Prohemocytes, Smoothened Inhibitor",
author = "Giorgia Giordani and Marilena Barraco and Angela Giangrande and Giovanni Martinelli and Viviana Guadagnuolo and Giorgia Simonetti and Giovanni Perini and Roberto Bernardoni",
year = "2016",
month = "7",
day = "28",
doi = "10.18632/oncotarget.10879",
language = "English",
volume = "7",
pages = "55313--55327",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "34",

}

Giordani, G, Barraco, M, Giangrande, A, Martinelli, G, Guadagnuolo, V, Simonetti, G, Perini, G & Bernardoni, R 2016, 'The Human Smoothened Inhibitor PF-04449913 Induced Exit from Quiescence and Loss of Multipotent Drosphila Hematopoietic Progenitor Cells', Oncotarget, vol. 7, no. 34, pp. 55313-55327. https://doi.org/10.18632/oncotarget.10879

The Human Smoothened Inhibitor PF-04449913 Induced Exit from Quiescence and Loss of Multipotent Drosphila Hematopoietic Progenitor Cells. / Giordani, Giorgia; Barraco, Marilena; Giangrande, Angela; Martinelli, Giovanni; Guadagnuolo, Viviana; Simonetti, Giorgia; Perini, Giovanni; Bernardoni, Roberto.

In: Oncotarget, Vol. 7, No. 34, 28.07.2016, p. 55313-55327.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Human Smoothened Inhibitor PF-04449913 Induced Exit from Quiescence and Loss of Multipotent Drosphila Hematopoietic Progenitor Cells

AU - Giordani, Giorgia

AU - Barraco, Marilena

AU - Giangrande, Angela

AU - Martinelli, Giovanni

AU - Guadagnuolo, Viviana

AU - Simonetti, Giorgia

AU - Perini, Giovanni

AU - Bernardoni, Roberto

PY - 2016/7/28

Y1 - 2016/7/28

N2 - The efficient treatment of hematological malignancies as Acute Myeloid Leukemia, myelofibrosis and Chronic Myeloid Leukemia, requires the elimination of cancerinitiating cells and the prevention of disease relapse through targeting pathways that stimulate generation and maintenance of these cells. In mammals, inhibition of Smoothened, the key mediator of the Hedgehog signaling pathway, reduces Chronic Myeloid Leukemia progression and propagation. These findings make Smo a candidate target to inhibit maintenance of leukemia-initiating cells. In Drosophila melanogaster the same pathway maintains the hematopoietic precursor cells of the lymph gland, the hematopoietic organ that develops in the larva. Using Drosophila as an in vivo model, we investigated the mode of action of PF-04449913, a smallmolecule inhibitor of the human Smo protein. Drosophila larvae fed with PF-04449913 showed traits of altered hematopoietic homeostasis. These include the development of melanotic nodules, increase of circulating hemocytes, the size increase of the lymph gland and accelerated differentiation of blood cells likely due to the exit of multi-potent precursors from quiescence. Importantly, the Smo inhibition can lead to the complete loss of hematopoietic precursors. We conclude that PF-04449913 inhibits Drosophila Smo blocking the Hh signaling pathway and causing the loss of hematopoietic precursor cells. Interestingly, this is the effect expected in patients treated with PF-04449913: Number decrease of cancer initiating cells in the bone marrow to reduce the risk of leukemia relapse. Altogether our results indicate that Drosophila comprises a model system for the in vivo study of molecules that target evolutionary conserved pathways implicated in human hematological malignancies.

AB - The efficient treatment of hematological malignancies as Acute Myeloid Leukemia, myelofibrosis and Chronic Myeloid Leukemia, requires the elimination of cancerinitiating cells and the prevention of disease relapse through targeting pathways that stimulate generation and maintenance of these cells. In mammals, inhibition of Smoothened, the key mediator of the Hedgehog signaling pathway, reduces Chronic Myeloid Leukemia progression and propagation. These findings make Smo a candidate target to inhibit maintenance of leukemia-initiating cells. In Drosophila melanogaster the same pathway maintains the hematopoietic precursor cells of the lymph gland, the hematopoietic organ that develops in the larva. Using Drosophila as an in vivo model, we investigated the mode of action of PF-04449913, a smallmolecule inhibitor of the human Smo protein. Drosophila larvae fed with PF-04449913 showed traits of altered hematopoietic homeostasis. These include the development of melanotic nodules, increase of circulating hemocytes, the size increase of the lymph gland and accelerated differentiation of blood cells likely due to the exit of multi-potent precursors from quiescence. Importantly, the Smo inhibition can lead to the complete loss of hematopoietic precursors. We conclude that PF-04449913 inhibits Drosophila Smo blocking the Hh signaling pathway and causing the loss of hematopoietic precursor cells. Interestingly, this is the effect expected in patients treated with PF-04449913: Number decrease of cancer initiating cells in the bone marrow to reduce the risk of leukemia relapse. Altogether our results indicate that Drosophila comprises a model system for the in vivo study of molecules that target evolutionary conserved pathways implicated in human hematological malignancies.

KW - Drosophila

KW - Leukemia

KW - PF-04449913

KW - Prohemocytes

KW - Smoothened Inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84983528617&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10879

DO - 10.18632/oncotarget.10879

M3 - Article

VL - 7

SP - 55313

EP - 55327

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 34

ER -